-
Something wrong with this record ?
Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient
D. Vrbata, J. Červený, N. Kulik, M. Hovorková, S. Balogová, M. Vlachová, H. Pelantová, V. Křen, P. Bojarová
Language English Country United States
Document type Journal Article
- MeSH
- Galectins * metabolism MeSH
- Humans MeSH
- Carbohydrates chemistry MeSH
- Thiogalactosides * chemistry MeSH
- Protein Binding MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The binding of human galectins by glycomimetic inhibitors is a promising therapeutic approach. The structurally distinct group of tandem-repeat galectins has scarcely been studied so far, and there is hardly any knowledge on their ligand specificity or their inhibitory potential, particularly concerning non-natural carbohydrates. Here, we present the synthesis of a library of seven 3-O-disubstituted thiodigalactoside-derived glycomimetics and their affinity to two tandem-repeat galectins, Gal-8 and Gal-9. The straightforward synthesis of these glycomimetics involved dibutyltin oxide-catalyzed 3,3́-O-disubstitution of commercially available unprotected thiodigalactoside, and conjugation of various aryl substituents by copper-catalyzed Huisgen azide-alkyne cycloaddition (CuAAC). The inhibitory potential of the prepared glycomimetics for Gal-8 and Gal-9 was assessed, and compared with the established galectins Gal-1 and Gal-3. The introduction of C-3 substituents resulted in an over 40-fold increase in affinity compared with unmodified TDG. The structure-affinity relations within the studied series were discussed using molecular modeling. Furthermore, the prepared glycomimetics were shown to scavenge Gal-8 and Gal-9 from the surface of cancer cells. This pioneering study on the synthetic inhibitors especially of Gal-9 identified lead compounds that may be used in further biomedical research.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006537
- 003
- CZ-PrNML
- 005
- 20240423155335.0
- 007
- ta
- 008
- 240412e20240220xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bioorg.2024.107231 $2 doi
- 035 __
- $a (PubMed)38394919
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vrbata, David $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic
- 245 10
- $a Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient / $c D. Vrbata, J. Červený, N. Kulik, M. Hovorková, S. Balogová, M. Vlachová, H. Pelantová, V. Křen, P. Bojarová
- 520 9_
- $a The binding of human galectins by glycomimetic inhibitors is a promising therapeutic approach. The structurally distinct group of tandem-repeat galectins has scarcely been studied so far, and there is hardly any knowledge on their ligand specificity or their inhibitory potential, particularly concerning non-natural carbohydrates. Here, we present the synthesis of a library of seven 3-O-disubstituted thiodigalactoside-derived glycomimetics and their affinity to two tandem-repeat galectins, Gal-8 and Gal-9. The straightforward synthesis of these glycomimetics involved dibutyltin oxide-catalyzed 3,3́-O-disubstitution of commercially available unprotected thiodigalactoside, and conjugation of various aryl substituents by copper-catalyzed Huisgen azide-alkyne cycloaddition (CuAAC). The inhibitory potential of the prepared glycomimetics for Gal-8 and Gal-9 was assessed, and compared with the established galectins Gal-1 and Gal-3. The introduction of C-3 substituents resulted in an over 40-fold increase in affinity compared with unmodified TDG. The structure-affinity relations within the studied series were discussed using molecular modeling. Furthermore, the prepared glycomimetics were shown to scavenge Gal-8 and Gal-9 from the surface of cancer cells. This pioneering study on the synthetic inhibitors especially of Gal-9 identified lead compounds that may be used in further biomedical research.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a vazba proteinů $7 D011485
- 650 12
- $a galektiny $x metabolismus $7 D037161
- 650 12
- $a thiogalaktosidy $x chemie $7 D013862
- 650 _2
- $a sacharidy $x chemie $7 D002241
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Červený, Jakub $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic; Department of Analytical Chemistry, Faculty of Science, Charles University, Hlavova 8, CZ-128 43 Prague 2, Czech Republic
- 700 1_
- $a Kulik, Natalia $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic
- 700 1_
- $a Hovorková, Michaela $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic; Department of Genetics and Microbiology, Faculty of Science, Charles University, Viničná 5, CZ-128 43 Prague 2, Czech Republic
- 700 1_
- $a Balogová, Soňa $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic; Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, CZ-128 43 Prague 2, Czech Republic
- 700 1_
- $a Vlachová, Miluše $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic
- 700 1_
- $a Pelantová, Helena $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic
- 700 1_
- $a Křen, Vladimír $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic
- 700 1_
- $a Bojarová, Pavla $u Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ-142 00, Prague 4, Czech Republic; Department of Health Care Disciplines and Population Protection, Faculty of Biomedical Engineering, Czech Technical University in Prague, nám. Sítná 3105, CZ-272 01 Kladno, Czech Republic. Electronic address: bojarova@biomed.cas.cz
- 773 0_
- $w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 145 (20240220), s. 107231
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38394919 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155331 $b ABA008
- 999 __
- $a ok $b bmc $g 2080870 $s 1216304
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 145 $c - $d 107231 $e 20240220 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
- LZP __
- $a Pubmed-20240412
